TrakCel, a Cardiff, Wales-based supplier of cellular orchestration solutions supporting the cell and gene therapy industry, closed its latest funding round of undisclosed amount.
The round was led by AmerisourceBergen and Labcorp (NYSE: LH).
These funds will enable further transformation of TrakCel’s cellular therapy orchestration solution, growth of its existing partner ecosystem, and continued global expansion. The company will use both the investment and the combined expertise gained from collaborations with the investors to further augment its offering to both clinical and commercial-stage cell and gene therapy developers as part of its drive toward industry standardization and future innovation.
Led by Ravi Nalliah, Chief Strategy Officer and Co-Founder, TrakCel is a developer of integrated technologies to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. Its solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining treatment collection to administration compliance and traceability.
TrakCel has developed a broad portfolio of live deployments in the industry across a range of therapies, from autologous and allogeneic therapies, personalized cancer vaccines and CRISPR, to tumor and marrow infiltrating lymphocyte therapies.